Patent ID: 7727527

Claim:
A method of controlling pain, thermal hyperalgesia and airway hyperreactivity in a human patient suffering therefrom without significantly adversely affecting the immune system of said patient, comprising administering to said patient an effective amount of an anti-human NGF (anti-hNGF) monoclonal antibody capable of binding hNGF with an affinity in the nanomolar or sub-nanomolar range, and inhibiting the binding of hNGF to human TrkA (hTrkA) in vivo, wherein said anti-hNGF monoclonal antibody is selected from MAb911 (ATCC Accession No. PTA-9141), MAb911 variants comprising a different glycosylation pattern, MAb911 chimeric antibodies, monoclonal antibodies that bind the same hNGF epitope as MAb911 and antigen-binding fragments of said antibodies, and wherein said anti-hNGF monoclonal antibody has no significant adverse effect on the immune system of said patient.